Literature DB >> 24166912

CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert.

Yuwen Zhu1, Lieping Chen.   

Abstract

Although human cancer is often surrounded by immune cells, only a small number are tumor-reactive T cells that recognize the tumor antigens and are able to eliminate the cancer cells. Ye and colleagues now found that many of these tumor-reactive T cells are marked by expressing CD137, a T-cell costimulatory receptor.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24166912     DOI： 10.1158/1078-0432.CCR-13-2573

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers.

Authors:  Yu Tian; Yi Sun; Fan Gao; Michelle R Koenig; Alexander Sunderland; Yuki Fujiwara; Robert J Torphy; Lieping Chen; Barish H Edil; Richard D Schulick; Yuwen Zhu
Journal:  Oncoimmunology       Date:  2018-11-05       Impact factor: 8.110

2.  Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Authors:  Lelisa F Gemta; Peter J Siska; Marin E Nelson; Xia Gao; Xiaojing Liu; Jason W Locasale; Hideo Yagita; Craig L Slingluff; Kyle L Hoehn; Jeffrey C Rathmell; Timothy N J Bullock
Journal:  Sci Immunol       Date:  2019-01-25

3.  Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.

Authors:  Dafne C A Quixabeira; Sadia Zafar; Joao M Santos; Victor Cervera-Carrascon; Riikka Havunen; Tatiana V Kudling; Saru Basnet; Marjukka Anttila; Anna Kanerva; Akseli Hemminki
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

4.  A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.

Authors:  Jing Zhou; Michael T Bethune; Natalia Malkova; Alexander M Sutherland; Begonya Comin-Anduix; Yapeng Su; David Baltimore; Antoni Ribas; James R Heath
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

5.  Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.

Authors:  Janina Kuen; Diana Darowski; Tobias Kluge; Meher Majety
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

6.  Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer.

Authors:  Muzamil Yaqub Want; Anna Konstorum; Ruea-Yea Huang; Vaibhav Jain; Satoko Matsueda; Takemasa Tsuji; Amit Lugade; Kunle Odunsi; Richard Koya; Sebastiano Battaglia
Journal:  Oncoimmunology       Date:  2019-03-30       Impact factor: 7.723

7.  Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.

Authors:  Maria A S Broggi; Lea Maillat; Cristina C Clement; Natacha Bordry; Patricia Corthésy; Aymeric Auger; Maurice Matter; Romain Hamelin; Lambert Potin; Davide Demurtas; Emanuela Romano; Alexandre Harari; Daniel E Speiser; Laura Santambrogio; Melody A Swartz
Journal:  J Exp Med       Date:  2019-04-11       Impact factor: 14.307

8.  Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.

Authors:  Daniela Di Blasi; Tujana Boldanova; Lucia Mori; Luigi Terracciano; Markus H Heim; Gennaro De Libero
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-08-22

9.  The GPR171 pathway suppresses T cell activation and limits antitumor immunity.

Authors:  Yuki Fujiwara; Robert J Torphy; Yi Sun; Emily N Miller; Felix Ho; Nicholas Borcherding; Tuoqi Wu; Raul M Torres; Weizhou Zhang; Richard D Schulick; Yuwen Zhu
Journal:  Nat Commun       Date:  2021-10-06       Impact factor: 14.919

Review 10.  Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Authors:  Natalia Krzyżanowska; Kamila Wojas-Krawczyk; Janusz Milanowski; Paweł Krawczyk
Journal:  Int J Mol Sci       Date:  2022-03-13       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.